Case report of endoprosthesis -Y implantation in severe respiratory failure in the MPSII patient; comparison with literature data

Wojciech Gocyk1, Janusz Warmus1, H Olechnowicz1, Mirosław Bik-Multanowski2, Łukasz Pawliński3, Beata Kieć‐Wilk3
1Department of Thoracic Surgery, John Paul II Hospital Krakow, Krakow, Poland
2Clinical Department of Medical Genetics, Children University Hospital, Krakow, Poland
3Clinical Department of Metabolic Diseases, University Hospital, Krakow, Poland

Tóm tắt

Abstract Background The tracheobronchomalacia is a life-threatening complication of mucopolysaccharidosis (MPS) without known effective, optimal treatment. The severe expiratory collapse of the trachea and bronchi is one of causes of the high rate of deaths in the course of airway impairment in MPSII patients. Case presentation Due to the adynamic tracheobronchomalacia despite of enzymatic treatment (ERT) in our MPSII patient, a life-saving tracheal bifurcated type-Y endoprosthesis (a self-expanding, metal stent for the prosthesis of tracheal and bronchial stenosis) was implanted. In the followed months, the breathing efficiency improved, but then gradual worsening, progression of bronchi occlusion at the stent border resulted in patient’s death. Conclusion The Y-stent implantation appears to be a short-term, life-saving solution without satisfactory long-term effects due to the progress of peripheral bronchomalacia and increased tissue proliferation and granulation, that arises during the illness’ course.

Từ khóa


Tài liệu tham khảo

Rutten M, Ciet P, van den Biggelaar R, et al. Severe tracheal and bronchial collapse in adults with type II mucopolysaccharidosis. Orphanet J Rare Dis. 2016;11:50. https://doi.org/10.1186/s13023-016-%200425-z.

Scarpa M, Almássy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011;6:72. https://doi.org/10.1186/1750-1172-6-72.

Jones SA, Almássy Z, Beck M, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the hunter outcome survey (HOS). J Inherit Metab Dis. 2009;32:534–43.

Lin HY, Chuang CK, Huang YH, et al. Causes of death and clinical characteristics of 34 patients with Mucopolysaccaridosis II in Taiwan fraom 1995-2012. Orphanet Journal of rare Disease. 2016;11:85. https://doi.org/10.1186/s13023-016-0471-6.

Lin SP, Shih SC, Chuang CK, et al. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses–changes with age and treatment. Pediatr Pulmonol. 2014;49:277–84.

Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44:117–26.

Berger KI, Fagondes SC, Giugliani R, et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis. 2013;36:201–10.

Cheng G, Chang FJ, Wang Y, et al. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up. Med Sci Monit. 2019;25:240–7.

Megens JH, de Wit M, van Hasselt PM, et al. Perioperative complications in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic stem cell transplantation at early age. Paediatr Anaesth. 2014;24:521–7.

Walker R, Belani KG, Braulin EA, et al. Anaesthesia and airway management in mucopolysccharidosis. J Inherit Metab Dis. 2013;36:211–9.

Karl R, Carola S, Regina E, Thomas N, Huber RM. Tracheobronchial stents in mucopolysaccharidosis. Int J Pediatr Otorhinolaryngol. 2016;83:187–92.

Kampmann C, Wiethoff CM, Huth RG, et al. Management of life-threatening tracheal stenosis and tracheomalacia in patients with mucopolysaccharidoses. J Inherit Metab Dis Rep. 2017;33:33–9. https://doi.org/10.1007/8904_2016_578.

Kamin W. Diagnosis and management of respiratory involvement in hunter syndrome. Acta Paediatr. 2008;97:57–60.